Agreement signedPublished 8 Nov 2022

Chiesi Farmaceutici S.p.A. /
PhaseBio Pharmaceuticals, Inc.

Chiesi Farmaceutici to buy PhaseBio assets in bankruptcy sale

Price
$40m
Stage
Agreement signed
Buy side: Chiesi Farmaceutici S.p.A.
Buy sideChiesi Farmaceutici S.p.A.
Target: PhaseBio Pharmaceuticals, Inc.
TargetPhaseBio Pharmaceuticals, Inc.
Source · 8 Nov 2022
Buy side: Chiesi Farmaceutici S.p.A.
Buy sideChiesi Farmaceutici S.p.A.
Target: PhaseBio Pharmaceuticals, Inc.
TargetPhaseBio Pharmaceuticals, Inc.
01 / BuyerChiesi Farmaceutici S.p.A.
02 / TargetPhaseBio Pharmaceuticals, Inc.
01

What happened

Chiesi Farmaceutici S.p.A. agreed to acquire PhaseBio Pharmaceuticals, Inc.’s assets primarily connected to bentracimab, including intellectual property, regulatory documentation and goodwill. The agreement also provides for the assumption of certain liabilities.

The offer includes approximately $40 million in cash at closing and future contingent payments of up to $60 million. The transaction remains subject to bankruptcy court approval and higher or otherwise better bids.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Chiesi Farmaceutici to buy PhaseBio assets in bankruptcy sale

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.